NXT-Dx

NXT-Dx is a Belgium-based life sciences services company focused on epigenetics and multi-omics research support. The company has offered start-to-finish research testing services spanning DNA methylation analysis, next-generation sequencing, transcriptomics, proteomics, immunoassays, and bioinformatics. Its capabilities have included targeted DNA methylation assays, RNA sequencing, exome and whole-genome sequencing, and custom assay development for biomarker discovery and validation. NXT-Dx appears to have operated primarily as a commercial research services provider rather than a therapeutics developer, supporting academic and industry customers in translational research. The company was acquired by Diagenode in August 2018 to expand Diagenode's epigenetics and assay services offering.